Pfizer announced detailed results from the pivotal Phase 3 TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway… read more.
Including blueberries, plums, blackberries, broad beans or cherries (washed down with green tea) in your five-a-day may be the best way to a healthier heart, new research suggests. A major research study involving scientists from the University of Reading, Harvard Medical… read more.
Fear can be used strategically in public health messaging to encourage people to quit smoking and avoid tobacco use, according to a joint study by researchers from the… read more.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity, as well as improvements… read more.
The MHRA has authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH). In patients with MASH, a protein called thyroid hormone receptor beta… read more.
A new review from the International Osteoporosis Foundation (IOF) Osteoimmunology Working Group, published in Osteoporosis International, provides a comprehensive evaluation of the role of vitamin D in inflammatory… read more.
A “nudging” strategy in the emergency department (ED) may be a path for prescribing a medication that can blunt cravings for alcohol—and dull its effects—offering an effective treatment for people… read more.
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at… read more.
Eli Lilly and Company announced positive topline results from the Phase III LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary… read more.
Researchers found postoperative delirium was strongly associated with long-term cognitive decline and the effect was not explained by rehospitalizations, highlighting the long-term impact of delirium on brain health…. read more.
A new Canadian study has found that social anxiety disorder (SAD) now affects nearly 1 in 7 adults — a 71% increase since 2002 — making it one… read more.
AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
